

Alpha Thalassemia - Pipeline Insight, 2021

<https://marketpublishers.com/r/AF44E2F0B7ADEN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: AF44E2F0B7ADEN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Alpha Thalassemia – Pipeline Insight, 2021," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Alpha Thalassemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Alpha Thalassemia Understanding

Alpha Thalassemia: Overview

Alpha thalassemia is an inherited blood disorder that results in the reduced production of haemoglobin. Haemoglobin is an essential protein that is involved in the transportation of oxygen throughout the body. Alpha thalassemia is caused due to mutations in genes responsible for the production of alpha globin. Depending on the number of alpha globin genes affected, it can result in four types of alpha thalassemia-silent alpha thalassemia, alpha thalassemia minor, haemoglobin H disease, and alpha thalassemia major or hydrops fetalis.

"Alpha Thalassemia - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication.

A detailed picture of the Alpha Thalassemia pipeline landscape is provided which includes the disease overview and Alpha Thalassemia treatment guidelines. The assessment part of the report embraces, in depth Alpha Thalassemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alpha Thalassemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Alpha Thalassemia R&D. The therapies under development are focused on novel approaches to treat/improve Alpha Thalassemia.

Alpha Thalassemia Emerging Drugs Chapters

This segment of the Alpha Thalassemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Alpha Thalassemia Emerging Drugs

Mitapivat: Agios, Inc.

Agios Inc's investigational drug candidate Mitapivat is an activator of mutated as well as normal pyruvate kinase-R (PKR) enzymes. The drug is primarily being studied for PK deficiency but the company has expanded their research and clinical application of mitapivat into thalassemia as well as sickle cell disease. The drug is currently in the Phase II trial for thalassemia. The U.S. Food and Drug Administration granted the Orphan Drug Status to mitapivat for the treatment of thalassemia.

Further product details are provided in the report.....

Alpha Thalassemia: Therapeutic Assessment

This segment of the report provides insights about the different Alpha Thalassemia drugs segregated based on following parameters that define the scope of the report,

such as:

Major Players in Alpha Thalassemia

There are approx. 4+ key companies which are developing the therapies for Alpha Thalassemia. The companies which have their Alpha Thalassemia drug candidates in the most advanced stage, i.e. phase II include, Agios, Inc.

Phases

DelveInsight's report covers around 4+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Alpha Thalassemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Subcutaneous

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Alpha Thalassemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alpha Thalassemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alpha Thalassemia drugs.

Alpha Thalassemia Report Insights

Alpha Thalassemia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Alpha Thalassemia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Alpha Thalassemia drugs?

How many Alpha Thalassemia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alpha Thalassemia?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Alpha Thalassemia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Alpha Thalassemia and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Agios , Inc.

Key Products

Mitapavit

Contents

Introduction

Executive Summary

Alpha Thalassemia: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Alpha Thalassemia – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Alpha Thalassemia companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Alpha Thalassemia Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase II)

Comparative Analysis

Mitapavit: Agios, Inc.

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Alpha Thalassemia Key Companies

Alpha Thalassemia Key Products

Alpha Thalassemia- Unmet Needs

Alpha Thalassemia- Market Drivers and Barriers

Alpha Thalassemia- Future Perspectives and Conclusion

Alpha Thalassemia Analyst Views

Alpha Thalassemia Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Alpha Thalassemia
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Alpha Thalassemia
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Alpha Thalassemia - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/AF44E2F0B7ADEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AF44E2F0B7ADEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970